Farmak, a leader of the domestic pharmaceutical industry, continues extending the oncology line of pharmaceutical products. Thus, Metakos, a new drug, is added to the Company’s portfolio.
This medicinal product is produced in the form of concentrate for solution for infusion (vial, 5 ml, No 1). Metakos contains zoledronic acid as active agent.
The medicinal product is prescribed for:
It is worth to remind that Farmak’s portfolio of pharmaceutical drugs for treatment of oncological diseases includes such products as Letromara (letrozole as active agent), Androfarm (cyproterone as active agent) and Flutafarm (flutamide as active agent).
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...